MedTrace Logo

Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults

NCT02833584 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2019-04-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether regular dosage of paracetamol causes transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.

Conditions

  • Dengue
  • Transaminitis

Interventions

DRUG

Paracetamol

Paracetamol 500 mg x 1 tablets according to patient's body weight

DRUG

Placebo

Placebo 500 mg x 1 tablets according to patient's body weight

Sponsors & Collaborators

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Principal Investigators

  • Dhitiwat Changpradub, MD · Phramongkutklao College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02833584 on ClinicalTrials.gov